
Opinion|Videos|November 6, 2023
Unmet Needs and Key Takeaways in CAP Management
Author(s)George Sakoulas, MD
George Sakoulas, MD, highlights persistent unmet needs in managing CAP and key takeways from ID week 2023.
Advertisement
Advertisement
Related to this article

In a target trial emulation using N3C data, adults prescribed metformin within six days of SARS-CoV-2 infection had about half the risk of long COVID or death within six months.

Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute infection and more than a quarter had completely remitted, in a large prospective cohort study.

A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.

Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.

The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.

Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.

Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
Half of Long COVID Patients Substantially Improve Within 3 years
2
Early Metformin Linked to 53% Lower Risk of Long COVID or Death
3
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
4
Washington State Reports First US Avian Influenza Death of 2026
5

